A5080468598- Pneumonia and Respiratory Infections
- Bacterial Infections and Vaccines
- Influenza Virus Research Studies
- Vaccine Coverage and Hesitancy
- Respiratory viral infections research
- Virology and Viral Diseases
- COVID-19 epidemiological studies
- Neonatal and Maternal Infections
- Pneumocystis jirovecii pneumonia detection and treatment
- Infective Endocarditis Diagnosis and Management
- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
- Streptococcal Infections and Treatments
- Hepatitis Viruses Studies and Epidemiology
- Cervical Cancer and HPV Research
- Reproductive tract infections research
- Viral Infections and Immunology Research
- Hepatitis B Virus Studies
- Global Maternal and Child Health
- Rabies epidemiology and control
- Viral Infections and Outbreaks Research
- Global Cancer Incidence and Screening
- Healthcare Policy and Management
- Preterm Birth and Chorioamnionitis
- Tracheal and airway disorders
University of Cambridge
2016-2025
Imperial College London
2024-2025
World Health Organization
2024
London School of Hygiene & Tropical Medicine
2013-2024
Medical Research Council
2024
Emory University
2024
Ashoka University
2023
Center for Disease Dynamics, Economics & Policy
2021-2023
St George's, University of London
2022
Public Health England
2005-2021
A serogroup meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) was licensed in India 2009, and pre-qualified by WHO 2010, on the basis of its safety immunogenicity. This is now being deployed across African meningitis belt. We studied effect PsA-TT carriage Chad during a epidemic.
The meningococcal group B vaccine 4CMenB is a new, recombinant protein-based that licensed to protect against invasive disease. However, its role in preventing transmission and, therefore, inducing population (herd) protection uncertain.
Background WHO, as requested by its member states, launched the Expanded Programme on Immunization (EPI) in 1974 to make life-saving vaccines available all globally.To mark 50-year anniversary of EPI, we sought quantify public health impact vaccination globally since programme's inception. MethodsIn this modelling study, used a suite mathematical and statistical models estimate global regional 50 years against 14 pathogens EPI.For modelled pathogens, considered coverage routine supplementary...
Abstract Pneumonia is an important cause of illness and death in England. To describe trends pneumonia hospitalizations, we extracted information on all episodes that occurred from April 1997 through March 2005 recorded the Hospital Episode Statistics (HES) database by searching for International Classification Diseases 10th revision codes J12–J18 any diagnostic field. The age-standardized incidence hospitalization with a primary diagnosis increased 34% 1.48 to 1.98 per 1,000 population...
Meningococcal serogroup C conjugate (MCC) vaccines were licensed in the United Kingdom more than 10 years ago based on correlates of protection that had previously been established for C-containing polysaccharide by using serum bactericidal antibody (SBA) assay. These subsequently validated against postlicensure estimates observed vaccine effectiveness up to 7 9 months after administration MCC vaccine. Vaccine was, however, shown fall significantly 1 year a 3-dose course infancy. Despite...
Much interest has surrounded the use of conjugate vaccines in recent years, with development against disease caused by Haemophilus influenzae type b, Neisseria meningitidis, and Streptococcus pneumoniae. These offer potential for safe effective control, but some questions remain, particularly regarding duration mechanisms protection longer-term impact vaccination on carriage. In this paper, authors data immunization serogroup C meningococcal England Wales to develop apply a mathematical...
<b>Objective</b> To use mathematical and economic models to predict the epidemiological impact of vaccination with Bexsero, designed protect against group B meningococcal disease, help inform vaccine policy in United Kingdom. <b>Design</b> Modelling study. <b>Setting</b> England. <b>Population</b> People aged 0-99. <b>Interventions</b> Incremental introductory strategies simulated a transmission dynamic model infection including potential herd effects. Model parameters included recent...
Meningococcal disease remains an important cause of morbidity and mortality worldwide. The first broadly effective vaccine against group B (which causes considerable meningococcal in Europe, the Americas Australasia) was licensed EU January 2013; our objective to estimate potential impact introducing such a England. We developed two models new 'MenB' vaccine. cohort model assumes protects only; transmission dynamic also allows protect carriage (accounting for herd effects). used these,...
Infant 13-valent pneumococcal conjugate vaccination (PCV13) was introduced to the UK in 2010. Its impact on serotypes implicated adult non-bacteraemic pneumonia is not known. Beginning 2008, a 5-year prospective cohort study of adults admitted hospital with community-acquired (CAP) conducted. Pneumococcal serotype established using validated multiplex immunoassay (Bio-Plex; Bio-Rad, Hercules, CA, USA). The overall incidence for hospitalised CAP and 79.9 (95% CI 76.6–83.3) 23.4 21.6–25.3) per...
<h3>Background</h3> The distribution of pneumococcal serotypes implicated in non-invasive community-acquired pneumonia (CAP) adults is currently unknown. <h3>Methods</h3> A prospective observational cohort study was conducted over 2 years a large UK teaching hospital trust. Urine samples, addition to routine blood and sputum were obtained from consecutive admitted the with CAP. Pneumococcal serotype determined urine samples using validated multiplex immunoassay which detects 14 serotypes....
Tens of thousands people die from dog-mediated rabies annually. Deaths can be prevented through post-exposure prophylaxis for who have been bitten, and the disease eliminated dog vaccination. Current use saves many lives, but availability remains poor in rabies-endemic countries due to high costs, access, supply.